iVacALL Trial: Prospective phase I/II study: Patient‐individualized peptide vaccination based on whole exome sequencing with adjuvant GM‐CSF and IFNα in children with relapsed acute lymphoblastic leukemia. This evidence concerns the gene CSF2 and acute lymphoblastic leukemia.